news about tirzepatide https://investor.lilly.com/news-releases/news-release-details/zepbound- tirzepatide-most-prescribed-weight-management “Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound Tirzepatide is a New Medication

4 weeks for tirzepatide). Differentiate clear from safe: Drug clearance does not prove prior use is safe for lactation

Adult consequences of self-limited delayed puberty

US-SKZ-260031

The regulatory process required stability data at multiple time points and temperatures before this claim could appear on the label

The use of GLP1-RAs represents a potential risk for gallbladder or biliary tract diseases because GLP-1RAs may inhibit gallbladder motility and delay gallbladder emptying by suppressing secretion of cholecystokinin leading to sludging and stone formation

It helps protect nerves due to its antioxidant properties and the ability to increase acetylcholine production [2]